...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: New Trial: Continuation Protocol for ZEN003694 in mCRPC Patients
Reply New Message
Prev Message Back To Forum Threaded View Next Message

I think safe to make the comment that being that ZEN 3694 trial is not blinded that all parties involved like the results to this point to deserve continuation, I am wondering why it couldn't go straight to a phase 3 trial for the next 3 years , What really could use is a buyout or partnership for ZEN3684, this would help to legitimize the science IMO

3 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply